Grace Therapeutics (GRCE) Short term Debt (2019)
Grace Therapeutics (GRCE) posted Short term Debt of $1.4 million for Q1 2019.
Grace Therapeutics (GRCE) Short term Debt (2019) Analysis & Trends
Grace Therapeutics has reported Short term Debt for 1 years, with the latest figure at $1.4 million in Q1 2019.
- Quarterly Short term Debt changed N/A year-over-year to $1.4 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $1.4 million (changed N/A YoY) and the FY2019 annual result came in at $1.4 million, changed N/A from the prior year.
- Short term Debt steadied at $1.4 million in Q1 2019 per GRCE's latest filing.
- Over five years, Short term Debt peaked at $1.4 million in Q1 2019 and troughed at $1.4 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 1.37 Mn |